Close Video

FROM OUR READERS

The ACIR weekly newsletter is an invaluable resource for me as a cancer researcher and drug developer. The recent explosion of IO related literature makes it difficult to review everything that is published. The ACIR newsletter makes it accessible to the most important and significant research in IO. This allows me more time to focus on drug development and be confident that I am remaining current with a rapidly advancing field.

Jamie Rice, PhD. Senior Investigator, Project Lead

Silicon Therapeutics

I am deeply appreciative of the work that ACIR does. With the rapid expansion of the immunotherapy/immuno-oncology field, it can sometimes be difficult to stay up on the most current literature. ACIR does a great job in promoting (and summarizing in great cartoon format) interesting findings every week, especially promoting articles from journals that have slightly lower impact factors than Science and Nature. The exposure one of my own papers got from ACIR was very much appreciated and greatly helped get our findings out to more readers. Thanks for doing what you do ACIR, it truly is helping to advance the field and continue to improve outcomes for cancer patients

David Messenheimer, PhD. Senior Scientist, Cancer Immunology

Boehringer Ingelheim Pharmaceuticals

ACIR’s website is a breath of fresh air that energizes you. It helps you filter and choose the publications that might be interesting for your area of research in immuno-oncology. The graphical abstracts and summaries include a link to the original publication helping you track many articles that otherwise might have go unnoticed. It is a great effort and a fantastic tool to have!

Miguel Marin-Rodero, PhD. Immunology student

Harvard Medical school

Biotrial is specialized in early development with a focus on oncology, and ACIR provides our clinical operations team with a huge update on the field of immuno-oncology. By receiving a weekly update, Biotrial is kept up to date in terms of oncology innovation. The literature database is also very useful for building specific trainings for our team. As we are a mid-size CRO, the free and easy access to ACIR website and newsletters has become an essential resource for our organization. Thank you to the people who allow us to benefit from this opportunity.

Sophie Parent, CRAs Coordinator/Oncology Trials Referent

Biotrial

ENDORSEMENTS FROM LEADERS IN THE FIELD

The field of cancer immunotherapy has exploded in recent years, drawing on the creativity and experience of scientists, clinicians, and patient advocates. ACIR does an incredible job of bringing these groups together toward a common goal of eliminating cancer by disseminating important research findings to the community at large.

James Allison, PhD

Professor and Chair, Department of Immunology; Executive Director, Immunotherapy Platform; Director, Parker Institute for Cancer Immunotherapy; and Vivian L. Smith Distinguished Chair-Immunology at the University of Texas MD Anderson Cancer Center. 2018 Nobel Prize in Physiology or Medicine.

The field of cancer immunotherapy has exploded in recent years, drawing on the creativity and experience of scientists, clinicians, and patient advocates. ACIR does an incredible job of bringing these groups together toward a common goal of eliminating cancer by disseminating important research findings to the community at large.

James Allison, PhD

Professor and Chair, Department of Immunology; Executive Director, Immunotherapy Platform; Director, Parker Institute for Cancer Immunotherapy; and Vivian L. Smith Distinguished Chair-Immunology at the University of Texas MD Anderson Cancer Center. 2018 Nobel Prize in Physiology or Medicine.

As a researcher bridging the science and clinical translation of the exciting discoveries of cancer immunotherapy, I applaud the efforts of ACIR to help me, my post-docs and students, and my colleagues keep up to date on all the key innovations driving this field. New knowledge continually refines our current thinking and ACIR keeps that new knowledge fresh and at our fingertips.

Catherine Wu, MD

Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School; Institute Member, Broad Institute of Harvard and MIT

As a researcher bridging the science and clinical translation of the exciting discoveries of cancer immunotherapy, I applaud the efforts of ACIR to help me, my post-docs and students, and my colleagues keep up to date on all the key innovations driving this field. New knowledge continually refines our current thinking and ACIR keeps that new knowledge fresh and at our fingertips.

Catherine Wu, MD

Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School; Institute Member, Broad Institute of Harvard and MIT

There is a critical need to provide reliable information to physicians and researchers. Key limitations are the large amount of data that is being published and the multiple clinical trials available. I welcome the efforts by ACIR to make sense out of all this data and provide a reliable source of information for researchers in cancer immunotherapy.

Antoni Ribas, MD, PhD

Professor of Medicine, Surgery, Molecular and Medical Pharmacology at the University of California (UCLA); Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC); Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA

There is a critical need to provide reliable information to physicians and researchers. Key limitations are the large amount of data that is being published and the multiple clinical trials available. I welcome the efforts by ACIR to make sense out of all this data and provide a reliable source of information for researchers in cancer immunotherapy.

Antoni Ribas, MD, PhD

Professor of Medicine, Surgery, Molecular and Medical Pharmacology at the University of California (UCLA); Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC); Director of the Parker Institute for Cancer Immunotherapy (PICI) Center at UCLA

The work of ACIR is so beautifully targeted on something that has the potential of being truly useful even in the earliest stages. What a great idea!

John Petricciani, MD

President of the International Alliance for Biological Standardization (IABS); Former Director of the Center for Biologics at FDA and former Chief Medical Officer of the Biologicals Unit at WHO

The work of ACIR is so beautifully targeted on something that has the potential of being truly useful even in the earliest stages. What a great idea!

John Petricciani, MD

President of the International Alliance for Biological Standardization (IABS); Former Director of the Center for Biologics at FDA and former Chief Medical Officer of the Biologicals Unit at WHO

Our understanding of the interaction between the immune system and cancer cells, and also the ways to exploit this interaction clinically, is growing faster than ever before. There is no reliable source of information that can help clinicians and researchers in this field stay up-to-date, and by filling this gap, ACIR facilitates the development of effective cancer immunotherapies for an increasing number of patient groups.

Ton Schumacher, PhD

Deputy Director of the Netherlands Cancer Institute; Professor of Immunotechnology at Leiden University, The Netherlands; Chief Scientific Officer of Kite Pharma EU; SU2C-CRI Immunotherapy Dream Team member

Our understanding of the interaction between the immune system and cancer cells, and also the ways to exploit this interaction clinically, is growing faster than ever before. There is no reliable source of information that can help clinicians and researchers in this field stay up-to-date, and by filling this gap, ACIR facilitates the development of effective cancer immunotherapies for an increasing number of patient groups.

Ton Schumacher, PhD

Deputy Director of the Netherlands Cancer Institute; Professor of Immunotechnology at Leiden University, The Netherlands; Chief Scientific Officer of Kite Pharma EU; SU2C-CRI Immunotherapy Dream Team member

Cancer Immunotherapy is providing patients with novel and durable treatments and the number of available therapies keeps growing. The mission of ACIR is to accelerate the pace by which the field develops through mapping out the research and clinical landscapes and keeping track of key advances in the field. It has my total support!!

Robert D. Schreiber, PhD

Alumni Endowed Professor of Pathology and Immunology and Professor of Molecular Microbiology at Washington University School of Medicine, MO; Director of the Washington University Center for Human Immunology and Immunotherapy Programs; Associate Director of the Scientific Advisory Board to the CRI

Cancer Immunotherapy is providing patients with novel and durable treatments and the number of available therapies keeps growing. The mission of ACIR is to accelerate the pace by which the field develops through mapping out the research and clinical landscapes and keeping track of key advances in the field. It has my total support!!

Robert D. Schreiber, PhD

Alumni Endowed Professor of Pathology and Immunology and Professor of Molecular Microbiology at Washington University School of Medicine, MO; Director of the Washington University Center for Human Immunology and Immunotherapy Programs; Associate Director of the Scientific Advisory Board to the CRI

I fully support the important initiative of ACIR. The field of cancer immunotherapy grows at an exciting pace. Staying on top of foundational discoveries in the field, which is conveniently processed on ACIR, is key for coming up with important new hypotheses about immunotherapeutic cancer treatment strategies.

Glenn Dranoff, MD, PhD

Global Head of Immuno-Oncology, Novartis Institutes of BioMedical Research

I fully support the important initiative of ACIR. The field of cancer immunotherapy grows at an exciting pace. Staying on top of foundational discoveries in the field, which is conveniently processed on ACIR, is key for coming up with important new hypotheses about immunotherapeutic cancer treatment strategies.

Glenn Dranoff, MD, PhD

Global Head of Immuno-Oncology, Novartis Institutes of BioMedical Research

I fully endorse the mission of ACIR to provide a weekly synopsis of the scientific literature in cancer immunotherapy. The value of this approach has been clearly demonstrated by a program I have been involved in with the Prize4Life Foundation, which is dedicated to curing ALS. ALS Forum provides ALS research summaries as well as other content related to clinical trials and is widely used by the ALS research community to keep up to date.

Tom Maniatis, PhD

Chairman of the Department of Biochemistry and Molecular Biophysics at the Columbia University Medical Center (CUMC) in New York, and Director of the University wide Columbia Precision Medicine Initiative (CPMI)

I fully endorse the mission of ACIR to provide a weekly synopsis of the scientific literature in cancer immunotherapy. The value of this approach has been clearly demonstrated by a program I have been involved in with the Prize4Life Foundation, which is dedicated to curing ALS. ALS Forum provides ALS research summaries as well as other content related to clinical trials and is widely used by the ALS research community to keep up to date.

Tom Maniatis, PhD

Chairman of the Department of Biochemistry and Molecular Biophysics at the Columbia University Medical Center (CUMC) in New York, and Director of the University wide Columbia Precision Medicine Initiative (CPMI)

ACIR has identified a great way to meet the critical need of researchers and clinicians everywhere to stay up to date with the literature in the fast moving and life-saving field of cancer immunotherapy. This will be a fine living tribute to your son Matt and has the potential to help many future cancer victims!

James S. Economou, MD, PhD

Beaumont Professor of Surgery, Microbiology, Immunology and Molecular Genetics, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA)

ACIR has identified a great way to meet the critical need of researchers and clinicians everywhere to stay up to date with the literature in the fast moving and life-saving field of cancer immunotherapy. This will be a fine living tribute to your son Matt and has the potential to help many future cancer victims!

James S. Economou, MD, PhD

Beaumont Professor of Surgery, Microbiology, Immunology and Molecular Genetics, and Molecular and Medical Pharmacology at the University of California, Los Angeles (UCLA)

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.

Nir Hacohen, PhD

Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT

And you… what are you saying?

IN THE PRESS

Cancer Warriors: How ACIR Is Saving Lives with Information

Tina Chang
Thrive Global | 3/25/2021

When Ed Fritsch lost his wife to breast cancer, the retired scientist with a background in molecular biology became obsessed with cancer research. Digging into the troves of scientific literature daily, he stumbled upon immunotherapy and its use in treating cancer. Without missing a beat, he reached out to the guru of immunotherapy at the Dana-Farber Cancer Institute in Boston, Glenn Dranoff, and said he wanted to help. As luck would have it, they needed someone with the talent, background, and passion that Fritsch could offer, and he began the work that the MIT Technology Review would later describe as one of the most promising advances in cancer research today. Read more.

For Ed Fritsch, a Second Career in Immunotherapy

RL
Inside the Institute | 7/21/2020

An accomplished career in the biopharmaceutical industry behind him, Ed Fritsch, PhD, was a month away from retirement in 2009 when he and his wife, Jan, learned that the breast cancer she had been treated for five years earlier had returned. The opportunity for enjoyment to which they had both looked forward became, instead, a struggle with a relentless disease that would take her life a year and a half later ...READ MORE

Ed Fritsch: Fast-Tracking Cancer Immunotherapy Research

Pioneering Collective
Pioneering Collective | 8/8/2019

Pioneering Collective wrote a piece on Ed Fritsch, ACIR’s president and co-founder. Learn more about how he cloned the first human beta-globin gene, wrote “Molecular Cloning: The Laboratory Manual” and what brought him to work in cancer immunotherapy later in life. http://bit.ly/31wr2mV

Concord resident starts cancer research organization to honor late wife, son

Rob Fucci
Wicked Local Concord | 7/17/2019

To lose a loved one to cancer is a blow many people unfortunately experience. To lose two within four years would be enough for some to give up hope.

But for Concord resident Ed Fritsch, the loss of his wife, Jan, in 2011 and son, Matt, in 2015, gave him a new mission: to help all cancer patients... READ MORE

The priming power of cDC2s

Lauren Hitchings
Parker Institute for Cancer Immunotherapy | 4/24/2019

Lauren's article on cDC2s is hosted on the Parker Institute for Cancer Immunotherapy news website.

It is also listed in the media section of the University of California San Francisco, Helen Diller Family Comprehensive Cancer Center.

Spotlight of Spotlights: A Day in the Life of a Science Writing Co-op

Brynn Vessey
NU SCI | 5/24/2018

Cancer immunotherapy has become something of a prodigal child in the last few years. Techniques and ideas such as checkpoint blockades, which aim to modify some aspect of the cancer immunity cycle such as anti-PD-1 and anti-CTLA4 therapy, vaccines, adoptive T cell transfer, and CAR T cell therapy are rising to the forefront with papers and studies conducted at an advanced rate. With so much new knowledge aiding in the fight against cancer, it seems almost impossible to know where to begin to get acquainted with the field. That’s where Advancing Cancer Immunotherapy Research, or ACIR, comes in. https://nuscimag.com/spotlight...

Close Modal

Subscribe to our mailing list

GDPR Marketing Permissions

The Fritsch Foundation/ACIR.org will use the information you provide on this form to be in touch with you and to send you a weekly digest on cance immunotherapy. Click below to confirm that you want to receive the weekly digest by:

You can change your mind at any time by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at contact@acir.org. We will treat your information with respect and will never share it with any third-parties. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.